Context Therapeutics Inc. (CNTX) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 6 Buy.
The consensus price target is $5.25 (low: $4.50, high: $6.00), representing an upside of 109.2% from the current price $2.51.
Analysts estimate Earnings Per Share (EPS) of $-0.58 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.46 vs est $-0.58 (beat +20.7%). 2025: actual $-0.38 vs est $-0.35 (missed -8.5%). Analyst accuracy: 83%.
CNTX Stock — 12-Month Price Forecast
$5.25
▲ +109.16% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Context Therapeutics Inc., the average price target is $5.25, with a high forecast of $6.00, and a low forecast of $4.50.
The average price target represents a +109.16% change from the last price of $2.51.
Highest Price Target
$6.00
Average Price Target
$5.25
Lowest Price Target
$4.50
CNTX Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to Context Therapeutics Inc. in the past 3 months
EPS Estimates — CNTX
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.46
vs Est –$0.58
▲ 26.1% off
2025
Actual –$0.38
vs Est –$0.35
▼ 7.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CNTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
